Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 155 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Fountzilas, George [Clear All Filters]
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis..
Lancet Oncol. 11(8), 753-62.
(2010). Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial..
J Transl Med. 8, 108.
(2010). Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer..
Anticancer Res. 30(10), 4325-33.
(2010). A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population..
Nat Genet. 42(10), 885-92.
(2010). Mutational spectrum of APC and genotype-phenotype correlations in Greek FAP patients..
BMC Cancer. 10, 389.
(2010). Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis..
Clin Cancer Res. 16(8), 2427-34.
(2010). Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group..
Clin Breast Cancer. 10(3), 230-7.
(2010). Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study..
Anticancer Drugs. 21(8), 785-9.
(2010). A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer..
Cancer Chemother Pharmacol. 65(4), 649-60.
(2010). Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model..
BMC Cancer. 10, 45.
(2010).
(2010). Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study..
J Oncol. 2010, 709678.
(2010). Screening of the DNA mismatch repair genes MLH1, MSH2 and MSH6 in a Greek cohort of Lynch syndrome suspected families..
BMC Cancer. 10, 544.
(2010). The upgraded role of HER3 and HER4 receptors in breast cancer..
Crit Rev Oncol Hematol. 74(2), 73-8.
(2010). Carboplatin and paclitaxel in metastatic or recurrent cervical cancer..
Int J Gynecol Cancer. 19(4), 777-81.
(2009). Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer..
Clin Cancer Res. 15(20), 6454-61.
(2009). Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial..
Breast Cancer Res Treat. 116(1), 131-43.
(2009). The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models..
Strahlenther Onkol. 185(11), 743-50.
(2009). Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck..
Anticancer Res. 29(2), 529-38.
(2009). MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer..
J Oncol. 2009, 305908.
(2009).
(2009). Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment..
Clin Cancer Res. 15(19), 6258-66.
(2009). Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma..
J Clin Oncol. 27(25), 4068-75.
(2009). Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma..
J Clin Oncol. 27(6), 939-44.
(2009). Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics..
PLoS One. 4(11), e7746.
(2009).